Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $259.70, for a total value of $934,920.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $33,761. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $261.09 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $11.58 billion, a price-to-earnings ratio of 12.34 and a beta of 0.54. The firm has a 50 day moving average of $239.06 and a 200 day moving average of $230.10. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $268.21.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the previous year, the company posted $4.86 EPS. On average, sell-side analysts predict that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on UTHR shares. Wedbush restated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. Oppenheimer upped their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, May 2nd. Finally, SVB Leerink started coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $308.78.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Rise Advisors LLC acquired a new stake in United Therapeutics in the first quarter worth about $32,000. GAMMA Investing LLC acquired a new stake in United Therapeutics during the fourth quarter worth about $43,000. Benjamin F. Edwards & Company Inc. raised its position in United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new position in United Therapeutics in the third quarter valued at approximately $91,000. Finally, Janiczek Wealth Management LLC boosted its position in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.